A new market has emerged where defunct startups sell their entire operational histories—including codebases, internal communications, and go-to-market data—to AI labs and data brokers. This creates a new form of salvage value, turning years of failed effort into a valuable corpus for training next-generation models.

History shows pioneers who fund massive infrastructure shifts, like railroads or the early internet, frequently lose their investment. The real profits are captured later by companies that build services on top of the now-established, de-risked platform.

The biotech industry recently endured its own "dot-com bust." Post-COVID hype gave way to investor impatience with the sector's fundamental realities: it takes over 10 years and massive capital ($200B/year industry-wide) to get a drug approved, leading to a sharp market correction.

While many early investors in tech booms (e.g., telecom, AI) lose money, these 'bubbles' are not a societal waste. They fund the rapid construction of foundational infrastructure, like fiber optic networks or data centers, creating immense long-term value and options for future innovation that society ultimately benefits from.

When a biotech company shutters, it's not a total loss. The scientific dead ends it uncovers prevent others from wasting resources on the same path. These "failures" enrich the ecosystem with crucial knowledge and release experienced talent back into the market.

Colossal CEO Ben Lamb, a software entrepreneur with no biology background, approached top geneticist George Church seeking world-changing problems. His ability to build teams and secure capital, unconstrained by scientific dogma, was key to launching the ambitious de-extinction venture.

While disastrous for many investors, historical bubbles like the dot-com boom and railway mania left behind massively overbuilt infrastructure (fiber optics, rail networks). This infrastructure became cheap and abundant post-crash, enabling subsequent waves of innovation that benefited society for decades.

George Church calculates that spending ~$100 to sequence a citizen's genome yields a $10k-$100k return. This massive ROI comes from avoiding the ~$1 million lifetime cost of caring for the 3% of children born with severe Mendelian diseases, a benefit realized within two years.

The past few years in biotech mirrored the tech dot-com bust, driven by fading post-COVID exuberance, interest rate hikes, and slower-than-hoped commercialization of new modalities like gene editing. This was caused by a confluence of factors, creating a tough environment for companies that raised capital during the peak.